Infinity Pharmaceuticals, Inc.
INFI
INFI was delisted on the 13th of September, 2023.
63 hedge funds and large institutions have $80.2M invested in Infinity Pharmaceuticals, Inc. in 2018 Q3 according to their latest regulatory filings, with 11 funds opening new positions, 15 increasing their positions, 16 reducing their positions, and 12 closing their positions.
1,380% more call options, than puts
Call options by funds: $1.02M | Put options by funds: $69K
50% more capital invested
Capital invested by funds: $53.5M → $80.2M (+$26.6M)
2.19% more ownership
Funds ownership: 49.97% → 52.16% (+2.2%)
6% less repeat investments, than reductions
Existing positions increased: 15 | Existing positions reduced: 16
8% less first-time investments, than exits
New positions opened: 11 | Existing positions closed: 12
2% less funds holding
Funds holding: 64 → 63 (-1)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
NC
Northpointe Capital
Bloomfield Hills,
Michigan
|
+$1.09M |
| 2 |
OAM
Oxford Asset Management
Oxford,
United Kingdom
|
+$1.05M |
| 3 |
FI
Fosun International
Hong Kong,
China
|
+$742K |
| 4 |
OM
Opaleye Management
Boston,
Massachusetts
|
+$569K |
| 5 |
EIM
Essex Investment Management
Boston,
Massachusetts
|
+$413K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
MWNA
Marshall Wace North America
New York
|
-$701K |
| 2 |
PIM
Platinum Investment Management
Sydney Australia 2000,
Australia
|
-$289K |
| 3 |
AG
Algert Global
San Francisco,
California
|
-$139K |
| 4 |
Jacobs Levy Equity Management
Florham Park,
New Jersey
|
-$121K |
| 5 |
Goldman Sachs
New York
|
-$106K |
INFI Hedge Fund Activity: Q3 2018 in Review
63 of the 4,391 institutional investors tracked by Wall St. Rank reported a position in Infinity Pharmaceuticals, Inc. (INFI) for Q3 2018, worth a combined $80.2M — up 50% from $53.5M a quarter earlier.
Sellers outnumbered buyers: 12 funds closed out of INFI and 11 opened new positions — a net loss of 1 holder — while 16 trimmed existing stakes and 15 added.
The largest buyer was Northpointe Capital, opening a new position worth an estimated $1.09M. The largest seller was Marshall Wace North America, exiting entirely with an estimated $701K sold.
- 63 institutional investors held Infinity Pharmaceuticals, Inc. (INFI) as of Q3 2018, down from 64 in Q2 2018.
- Funds reported $80.2M of Infinity Pharmaceuticals, Inc. stock for Q3 2018, up 50% quarter-over-quarter.
- 11 funds opened new Infinity Pharmaceuticals, Inc. positions in Q3 2018 and 12 closed out, a net change of -1 holder.
- The largest Infinity Pharmaceuticals, Inc. buyer in Q3 2018 was Northpointe Capital, an estimated $1.09M added.
- The largest Infinity Pharmaceuticals, Inc. seller in Q3 2018 was Marshall Wace North America, an estimated $701K sold.
Based on aggregated 13F filings for Q3 2018.